Check this how Section 16. Fo

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
rm 4 or Form 5	
y continue. See	

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Instruc	tion 1(b).			File	d pursuan	t to Section 16(a)) of the S	ecuriti	es Exchan	ae Act of 1	934						
	. ,					tion 30(h) of the											
1. Name and Address of Reporting Person* <u>Kirschman David Louis</u>					2. Issuer Name and Ticker or Trading Symbol Xtant Medical Holdings, Inc. [BONE]					(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner						
(Last) 664 CRU	(F JISER LAN	(First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 10/12/2015						helow)	Officer (give title Other (specificelow) below) EVP & Chief Scientific Officer				
(Street)	Street) BELGRADE MT 59714				4. If Am	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	e) <mark>X</mark> Form f	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting				
(City)	(S		(Zip)									Person					
		Tab	le I - Nor	1-Deriv	ative Se	ecurities Acc	quired,	Disp	osed o	of, or Be	neficial	ly Owned	!				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D		Execution Date,		Transaction Disposed C Code (Instr. 5)		ities Acquired (A) o d Of (D) (Instr. 3, 4 a				6. Ownersh Form: Direc (D) or Indire (I) (Instr. 4)		of Indirect					
					С			v	Amount	(A) or (D)	Price	Transact (Instr. 3	tion(s)			(111301. 4)	
		-				urities Acqu ls, warrants,						Owned					
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, irity or Exercise (Month/Day/Year) if any		ransaction of Expiration Dat ode (Instr. Derivative (Month/Day/Ye			n Date		7. Title and Amount of Securities Underlying Derivative Securit		8. Price of Derivative Security (Instr. 5)			10. Ownership Form: Direct (D)	11. Nature of Indirect Beneficia Ownershi			

Explanation of Responses:

Price of Derivative

Security

Restricted

Stock Unit

- 1. Each restricted stock unit represents the contingent right to receive one share of Xtant Medical Holdings, Inc. common stock.
- 2. The restricted stock units vest as follows: (i) 20%, or 8,000 underlying shares, will vest on the first anniversary of the date of the grant, and (ii) the remaining 80% will vest in 35 equal monthly installments of 914 underlying shares, beginning one month after the first anniversary of the date of the grant, with the remaining 10 shares vesting on the fourth anniversary of the date of grant. Dr. Kirschman must remain employed by Xtant Medical Holdings, Inc. or its subsidiaries for vesting to occur.

Date

Exercisable

(2)

(D)

Expiration

(2)

Date

/s/ David Kirschman

Derivative Sec (Instr. 3 and 4)

Title

Common

Stock

10/12/2015

** Signature of Reporting Person

Amount or Number

Shares

40,000

Date

Beneficially Owned

Transaction(s) (Instr. 4)

40,000

Following

Reported

Direct (D) or Indirect

(I) (Instr. 4)

D

\$0

Beneficial

Ownership (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

10/12/2015

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

Α

Securities Acquired (A) or Disposed

of (D) (Instr. 3, 4 and 5)

(A)

40,000

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.